Western blot analysis of Phospho-IKK-alpha pSer176 /IKKbeta pSer177 in extracts from differentiated THP-1 cells, untreated or LPS-treated for 15 minutes, using Phospho-IKK-alpha pSer176 /IKKbeta pSer177 monoclonal antibody (Product # MA5-14857) (upper), IKK-alpha antibody (middle) and IKK-beta monoclonal antibody (lower).
|Tested species reactivity||Bovine, Human, Mouse, Non-human primate, Rat|
|Published species reactivity||Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic phosphopeptide corresponding to residues surrounding pSer177 of IKKß|
|Storage buffer||0.01M HEPES, pH 7.5, with 0.15M NaCl, 100µg/ml BSA, 50% glycerol|
|Contains||<0.02% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
It is not recommended to aliquot this antibody.
NFKB1 or NFKB2 is bound to REL, RELA, or RELB to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008, or NFKBIB, MIM 604495), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, or IKBKB) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-¿B impairs this drug-induced senescence.
MA5-14857 was used in western blot to report that induction of senescence and immune surveillance limit melanoma growth
|Liu Y,Hawkins OE,Su Y,Vilgelm AE,Sobolik T,Thu YM,Kantrow S,Splittgerber RC,Short S,Amiri KI,Ecsedy JA,Sosman JA,Kelley MC,Richmond A||EMBO molecular medicine (5:149)||2013|